According to a recent study published online in the journal The Lancet Oncology, researchers have found that doxorubicin plus trabectedin have activity as first-line treatment for uterine leiomyosarcoma and soft-tissue leiomyosarcoma.
Researchers sought to investigate the effect of first-line doxorubicin and trabectedin on disease control and survival in patients with metastatic leiomyosarcoma of uterine or soft-tissue origin in a single-group, multicenter, phase 2 study.
Researchers enrolled and treated 109 patients with doxorubicin 60mg/m2 intravenously and trabectedin 1.1mg/m2 intravenously on day 1, and pegfilgrastim 6mg subcutaneously on day 2, every 3 weeks for up to six cycles.
RELATED: Reduced Target Volume Significantly Reduces Late Toxicities in Extremity Sarcoma
Ultimately, 68% of those with uterine leiomyosarcoma and 74% of those with soft-tissue leiomyosarcoma received all six cycles. Results showed that 59.6% of patients with uterine disease achieved a partial response, 27.7% had stable disease, and 87.2% achieved disease control.
Of those with soft-tissue disease, 3.3% achieved a complete response, 36.1% achieved a partial response, 52.5% had stable disease, and 91.8% achieved disease control.